| Title |
CRTH2 antagonists in asthma: current perspectives
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, December 2017
|
| DOI | 10.2147/cpaa.s119295 |
| Pubmed ID | |
| Authors |
Dave Singh, Arjun Ravi, Thomas Southworth |
| Abstract |
Chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) binds to prostaglandin D2. CRTH2 is expressed on various cell types including eosinophils, mast cells, and basophils. CRTH2 and prostaglandin D2 are involved in allergic inflammation and eosinophil activation. Orally administered CRTH2 antagonists are in clinical development for the treatment of asthma. The biology and clinical trial data indicate that CRTH2 antagonists should be targeted toward eosinophilic asthma. This article reviews the clinical evidence for CRTH2 involvement in asthma pathophysiology and clinical trials of CRTH2 antagonists in asthma. CRTH2 antagonists could provide a practical alternative to biological treatments for patients with severe asthma. Future perspectives for this class of drug are considered, including the selection of the subgroup of patients most likely to show a meaningful treatment response. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 16% |
| Student > Ph. D. Student | 8 | 15% |
| Other | 6 | 11% |
| Student > Bachelor | 6 | 11% |
| Professor | 3 | 5% |
| Other | 10 | 18% |
| Unknown | 13 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 29% |
| Biochemistry, Genetics and Molecular Biology | 8 | 15% |
| Immunology and Microbiology | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 1 | 2% |
| Unknown | 16 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2020.
All research outputs
#7,359,319
of 25,382,440 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#74
of 179 outputs
Outputs of similar age
#134,959
of 444,941 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#3
of 5 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 444,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.